Gender-related risk of myocardial involvement in systemic amyloidosis

Amyloid

Volumn 15, Issue 1, 2008, Pages 40-48

  Rapezzi, Claudio ^a   Riva, Letizia ^a   Quarta, Cristina C ^a   Perugini, Enrica ^b   Salvi, Fabrizio ^c   Longhi, Simone ^a   Ciliberti, Paolo ^a   Pastorelli, Francesca ^c   Biagini, Elena ^a   Leone, Ornella ^a   Cooke, Robin M T ^a   Bacchi Reggiani, Letizia ^a   Ferlini, Alessandra ^d   Cavo, Michele ^a   Merlini, Giampaolo ^e   Perlini, Stefano ^e   Pasquali, Sonia ^a   Branzi, Angelo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b MAGGIORE HOSPITAL   (Italy)

^c BELLARIA HOSPITAL   (Italy)

^d UNIVERSITY OF FERRARA   (Italy)

^e FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Amyloidosis; Cardiomyopathies; Female; Male

Indexed keywords

PREALBUMIN;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; CARDIOMYOPATHY; ECHOCARDIOGRAPHY; FEMALE; GENDER; GENE MUTATION; HEART AMYLOIDOSIS; HEART LEFT VENTRICLE MASS; HEART VENTRICLE HYPERTROPHY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MENOPAUSE; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; SYSTEMIC DISEASE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AMYLOIDOSIS; CARDIOMYOPATHIES; ECHOCARDIOGRAPHY; FEMALE; GONADAL STEROID HORMONES; HEART VENTRICLES; HUMANS; MALE; MENOPAUSE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEX FACTORS;

EID: 39049117075     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.1080/13506120701815373     Document Type: Article

References (37)

1. Park MA, Mueller PS, Kyle RA, Larson DR, Plevak MF, Gertz MA. Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients. Medicine (Baltimore) 2003;82:291-298.
2. Witzig TE, Gertz MA, Lust JA, Kyle RA, O'Fallon WM, Greipp PR. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Blood 1996;88:1780-1787.
3. Rajkumar SV, Gertz MA, Kyle RA. Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy. Am J Med 1998;104:232-237.
4. Kyle RA, Therneau TM, Rajkumar SV, Remstein ED, Offord JR, Larson DR, Plevak MF, Melton LJ. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 2003;102:3759-3764.
5. Berk JL, Keane J, Seldin DC, Sanchorawala V, Koyama J, Dember LM, Falk RH. Persistent pleural effusions in primary systemic amyloidosis: etiology and prognosis. Chest 2003;124:969-977.
6. Alves M, Conceicao I, Luis ML. Neurophysiological evaluation of sexual dysfunction in familial amyloidotic polyneuropathy - Portuguese type. Acta Neurol Scand 1997;96:163-166.
7. Bittencourt PL, Couto CA, Clemente C, Farias AQ, Palacios SA, Mies S, Goldberg AC. Phenotypic expression of familial amyloid polyneuropathy in Brazil. Eur J Neurol 2005;12:289-293.
8. Ikeda S, Nakazato M, Ando Y, Sobue G. Familial transthyretin-type amyloid polyneuropathy in Japan. Clinical and genetic heterogeneity. Neurology 2002;58:1001-1007.
9. Misu K, Hattori N, Nagamatsu M, Ikeda S, Ando Y, Nakazato M, Takei Y, Hanyu N, Usui Y, Tanaka F, Harada T, Inukai A, Hashizume Y, Sobue G. Late-onset familial amyloid polyneuropathy type I (transthyretin met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan: clinicopathological and genetic features. Brain 1999;122:1951-1962.
10. Planté-Bordeneuve V, Carayol J, Ferreira A, Adams D, Clerget-Darpoux F, Misrahi M, Said G, Bonay ti-Pellié G. Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families. J Med Genet 2003;40:e120.
11. Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 2005;62:1057-1062.
12. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005;112:2047-2060.
13. Kyle RA, Spittell PC, Gertz MA, Li CY, Edwards WD, Olson LJ, Thibodeau SN. The premortem recognition of systemic senile amyloidosis with cardiac involvement. Am J Med 1996;101:395-400.
14. Ng B, Connors LH, Davidoff R, Skinner M, Falk RH. Senile systemic amyloidosis presenting with heart failure. A comparison with light chain-associated amyloidosis. Arch Intern Med 2005;165:1425-1429.
15. Rapezzi C, Perugini E, Salvi F. Female sex as a possible protective factor from myocardial involvement in transthyretin-related amyloidoses. Arch Intern Med 2005;165:2429.
16. Lachmann HJ, Booth DR, Booth SE, Bybee A, Gilbertson JA, Gillmore JD, Pepys MB, Hawkins PN. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002;346:1786-1791.
17. Ferlini A, Fini S, Salvi F, Patrosso MC, Vezzoni P, Forabosco A. Molecular strategies in genetic diagnosis of transthyretin-related hereditary amyloidosis. FASEB J 1992;6:2864-2866.
18. Palladini G, Perfetti V, Merlini G. Therapy and management of systemic AL (primary) amyloidosis. Swiss Med Wkly 2006;136:715-720.
19. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th international symposium on amyloid and amyloidosis. Am J Hematol 2005;79:319-328.
20. Coutinho P, Martins da Silva A, Lopes Lima J, Resende, Barbosa A. Forty years of experience with type I amyloid neuropathy. In: Glenner GG, Costa PP, Freitas AF, editors. Amyloid and amyloidosis. Amsterdam: Excerpta Medica; 1980. pp 88-98.
21. Rapezzi C, Perugini E, Salvi F, Grigioni F, Riva L, Cooke RM, Ferlini A, Rimessi P, Bacchi-Reggiani L, Ciliberti P, Pastorelli F, Leone O, Bartolomei I, Pinna AD, Arpesella G, Branzi A. Phenotypic and genotypic heterogeneity in transthyretin-related cardiac amyloidosis: towards tailoring of therapeutic strategies? Amyloid 2006;13:143-153.
22. Cheitlin MD, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davis JL, Douglas PS, Faxon DP, Gillam LD, Kimball TR, Kussmaul WG, Pearlman AS, Philbrick JT, Rakowski H, Thys DM, Antman EM, Smith SC Jr, Alpert JS, Gregoratos G, Anderson JL, Hiratzka LF, Hunt SA, Fuster V, Jacobs AK, Gibbons RJ, Russell RO; American College of Cardiology; American Heart Association; American Society of Echocardiography. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation 2003;108:1146-1162.
23. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450-458.
24. Garcia MJ, Thomas JD, Klein AL. New Doppler echocardiographic applications for the study of diastolic function. J Am Coll Cardiol 1998;32:865-875.
25. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997;337:898-909.
26. Leone O, Boriani G, Chiappini B, Pacini D, Cenacchi G, Martin Suarez S, Rapezzi C, Bacchi Reggiani ML, Marinelli G. Amyloid deposition as a cause of atrial remodelling in persistent valvular atrial fibrillation. Eur Heart J 2004;25:1237-1241.
27. Kawamura S, Takahashi M, Ishihara T, Uchino F. Incidence and distribution of isolated atrial amyloid: histologic and immunohistochemical studies of 100 aging hearts. Pathol Int 1995;45:335-342.
28. Rocken C, Peters B, Juenemann G, Saeger W, Klein HU, Huth C, Roessner A, Goette A. Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. Circulation 2002;106:2091-2097.
29. Goette A, Rocken C. Atrial amyloidosis and atrial fibrillation: a gender-dependent 'arrhythmogenic substrate'? Eur Heart J 2004;25:1185-1186.
30. Verdecchia P, Carini G, Circo A, Dovellini E, Giovannini E, Lombardo M, Solinas P, Gorini M, Maggioni AP; MAVI (MAssa Ventricolare sinistra nell'Ipertensione) Study Group. Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J Am Coll Cardiol 2001;38:1829-1835.
31. Devereux RB, Lutas EM, Casale PN, Kligfield P, Eisenberg RR, Hammond IW, Miller DH, Reis G, Alderman MH, Laragh JH. Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol 1984;4:1222-1230.
32. Liao Y, Cooper RS, Mensah GA, McGee DL. Left ventricular hypertrophy has a greater impact on survival in women than in men. Circulation 1995;92:805-810.
33. Coe JE, Ross MJ. Hamster female protein, a sex-limited pentraxin, is a constituent of Syrian hamster amyloid. J Clin Invest 1985;76:66-74.
34. Coe JE, Ross MJ. Amyloidosis and female protein in the Syrian hamster: concurrent regulation by sex hormones. J Exp Med 1990;171:1257-1267.
35. Yue X, Lu M, Lancaster T, Cao P, Honda S, Staufenbiel M, Harada N, Zhong Z, Shen Y, Li R. Brain estrogen deficiency accelerates Abeta plaque formation in an Alzheimer's disease animal model. Proc Natl Acad Sci USA 2005;102:19198-19203.
36. Barron AM, Fuller SJ, Verdile G, Martins RN. Reproductive hormones modulate oxidative stress in Alzheimer's disease. Antioxid Redox Signal 2006;11:2047-2059.
37. Petanceska SS, Nagy V, Frail D, Gandy S. Ovariectomy and 17β-estradiol modulate the levels of Alzheimer's amyloid β peptides in brain. Neurology 2000;54:2212-2217.